Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NAMSW
Upturn stock ratingUpturn stock rating

NewAmsterdam Pharma Company N.V. Warrant (NAMSW)

Upturn stock ratingUpturn stock rating
$13.6
Last Close (24-hour delay)
Profit since last BUY29.65%
upturn advisory
Consider higher Upturn Star rating
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: NAMSW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit -27.34%
Avg. Invested days 21
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -0.03
52 Weeks Range 5.45 - 16.75
Updated Date 05/17/2025
52 Weeks Range 5.45 - 16.75
Updated Date 05/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2314.47%

Management Effectiveness

Return on Assets (TTM) -18.15%
Return on Equity (TTM) -31.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 54899238
Shares Outstanding -
Shares Floating 54899238
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

NewAmsterdam Pharma Company N.V. Warrant

stock logo

Company Overview

overview logo History and Background

NewAmsterdam Pharma Company N.V. is a biopharmaceutical company focused on the research and development of therapies for metabolic diseases, particularly those affecting lipid metabolism. It went public through a reverse merger with Frazier Lifesciences Acquisition Corporation in 2022. The warrant represents the right to purchase shares of the combined company.

business area logo Core Business Areas

  • Lipid Metabolism Therapies: Develops and commercializes therapies targeting lipid metabolism, focusing on cardiovascular disease.

leadership logo Leadership and Structure

The leadership team comprises experienced pharmaceutical executives. The company has a typical organizational structure for a publicly traded biopharmaceutical firm, including research, development, and commercialization departments.

Top Products and Market Share

overview logo Key Offerings

  • Obicetrapib: Obicetrapib is their lead investigational product. It is a CETP inhibitor in Phase 3 clinical trials for lowering LDL cholesterol and reducing cardiovascular risk. Competitors include existing statins (e.g., Lipitor, Crestor) and other emerging lipid-lowering therapies like PCSK9 inhibitors (e.g., Repatha, Praluent). Market share is prospective, dependent on successful clinical trials and regulatory approval. No current revenue.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, especially the segment focused on cardiovascular diseases and lipid metabolism disorders, is a large and competitive market. Driven by aging populations and increasing prevalence of related conditions.

Positioning

NewAmsterdam Pharma aims to address unmet needs in lipid management, particularly for patients who do not achieve sufficient LDL-C lowering with existing therapies. Their success depends heavily on the clinical and commercial performance of Obicetrapib.

Total Addressable Market (TAM)

The global lipid-lowering drug market is estimated to be worth hundreds of billions of dollars. NewAmsterdam Pharma's positioning within this TAM is dependent on clinical trial outcomes and regulatory approval of Obicetrapib. If successful, they could capture a significant portion of the market currently addressed by statins and PCSK9 inhibitors.

Upturn SWOT Analysis

Strengths

  • Promising lead compound (Obicetrapib)
  • Experienced management team
  • Focus on a large and growing market

Weaknesses

  • Single product focus (Obicetrapib)
  • Reliance on clinical trial success
  • Potential for regulatory hurdles
  • No current product revenue

Opportunities

  • Potential for partnership or acquisition
  • Expansion into new indications
  • Positive clinical trial results
  • Favorable regulatory environment

Threats

  • Competition from established pharmaceutical companies
  • Failure of clinical trials
  • Adverse regulatory decisions
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • REGN
  • NVO

Competitive Landscape

NewAmsterdam Pharma faces significant competition from large, established pharmaceutical companies with extensive resources and existing products for lipid management. Their competitive advantage relies on demonstrating superior efficacy and safety of Obicetrapib.

Growth Trajectory and Initiatives

Historical Growth: Historical growth is non-existent as a clinical stage company without revenue.

Future Projections: Future growth is entirely dependent on the successful development and commercialization of Obicetrapib. Analyst estimates vary widely based on clinical trial assumptions.

Recent Initiatives: Focus on advancing Obicetrapib through Phase 3 clinical trials and preparing for potential regulatory submissions.

Summary

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company with a high-risk, high-reward profile. Its success hinges on the outcome of Obicetrapib's clinical trials and subsequent regulatory approval. The company faces strong competition and financial risks but also has the potential for significant growth if Obicetrapib proves to be a successful therapy. Investors should closely monitor clinical trial results and regulatory developments.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough due diligence and consultation with a qualified financial advisor. Data is subject to change without notice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About NewAmsterdam Pharma Company N.V. Warrant

Exchange NASDAQ
Headquaters -
IPO Launch date 2022-11-23
CEO, President, Executive Board Member & Director Dr. Michael Harvey Davidson FACC, Facp., M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 77
Full time employees 77

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.